Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group;Guía diagnóstica y terapéutica de las microangiopatías trombóticas del Grupo Español de Aféresis

Medicina Clinica

Volumn 144, Issue 7, 2015, Pages 331.e1-331.e13

  Contreras, Enric ^a   De La Rubia, Javier ^b   Del Río Garma, Julio ^c   Díaz Ricart, Maribel ^d   García Gala, José María ^e   Lozano, Miguel ^d  

^a Banc de Sang i Teixits Joan XXIIi   (Spain)

^b UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

^c Nephrology Department   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Apheresis; Hemolytic uremic syndrome; Plasma exchange; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

ARTICLE; HUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; THROMBOCYTOPHERESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; APHERESIS; CONSENSUS DEVELOPMENT; MULTIMODALITY CANCER THERAPY; PLASMAPHERESIS; THROMBOTIC MICROANGIOPATHIES;

IMMUNOSUPPRESSIVE AGENT;

BLOOD COMPONENT REMOVAL; COMBINED MODALITY THERAPY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMA EXCHANGE; THROMBOTIC MICROANGIOPATHIES;

EID: 84926216366     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2014.09.013     Document Type: Article

References (124)

1. E. Moschcowitz An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries; an undescribed disease Arch Intern Med 36 1925 89 93
2. J.M. Thurman New anti-complement drugs: Not so far away Blood. 123 2014 1975 1976
3. D.R. Terrell, L.A. Williams, S.K. Vesely, B. Lammle, J.A. Hovinga, and J.N. George The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: All patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency J Thromb Haemost. 3 2005 1432 1436
4. M. Scully, H. Yarranton, R. Liesner, J. Cavenagh, B. Hunt, and S. Benjamin Regional UK TTP registry: Correlation with laboratory ADAMTS 13 analysis and clinical features Br J Haematol. 142 2008 819 826
5. Y. Fujimura, and M. Matsumoto Registry of 919 patients with thrombotic microangiopathies across Japan: Database of Nara Medical University during 1998-2008 Intern Med. 49 2010 7 15
6. A.R. Constantinescu, M. Bitzan, L.S. Weiss, E. Christen, B.S. Kaplan, and A. Cnaan Non-enteropathic hemolytic uremic syndrome: Causes and short-term course Am J Kidney Dis. 43 2004 976 982
7. M. Furlan, R. Robles, and B. Lamie Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis Blood. 87 1996 4223 4234
8. H.M. Tsai Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion Blood. 87 1996 4235 4244
9. G.G. Levy, W.C. Nichols, E.C. Lian, T. Foroud, J.N. McClintick, and B.M. McGee Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura Nature 413 2001 488 494
10. J.L. Moake, C.K. Rudy, J.H. Troll, M.J. Weinstein, N.M. Colannino, and J. Azocar Unusually large plasma factor VIII: Von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura N Engl J Med 307 1982 1432 1435
11. J.L. Moake, N.A. Turner, N.A. Stathopoulos, L.H. Nolasco, and J.D. Hellums Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation J Clin Invest 78 1986 1456 1461
12. J.A. Cohen, M.E. Brecher, and N. Bandarenko Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura J Clin Apheresis 13 1998 16 19
13. M. Moatti-Cohen, C. Garrec, M. Wolf, P. Boisseau, L. Galicier, and E. Azoulay Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura Blood. 119 2012 5888 5897
14. R. Grillberger, V.C. Casina, P.L. Turecek, X.L. Zheng, H. Rottensteiner, and F. Scheiflinger Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura Haematologica 99 2014 e58 e60
15. H.M. Tsai Autoimmune thrombotic microangiopathy: Advances in pathogenesis, diagnosis, and management Semin Thromb Hemost. 38 2012 469 482
16. P. Coppo, M. Busson, A. Veyradier, A. Wynckel, P. Poullin, and E. Azoulay HLA-DRB1∗11: A strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians J Thromb Haemost. 8 2010 856 859
17. N. Sorvillo, S.D. van Haren, P.H. Kaijen, A. ten Brinke, R. Fijnheer, and A.B. Meijer Preferential HLA-DRB1∗11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells Blood. 121 2013 3502 3510
18. M. Bitzan, B.B. Bickford, and G.H. Foster Verotoxin (shiga toxin) sensitizes renal epithelial cells to increased heme toxicity: Possible implications for the hemolytic uremic syndrome J Am Soc Nephrol. 15 2004 2334 2343
19. P. Sánchez-Corral, and M. Melgosa Advances in understanding the aetiology of atypical haemolytic uraemic syndrome Br J Haematol. 150 2010 529 542
20. M. Noris, and G. Remuzzi Atypical hemolytic-uremic syndrome N Engl J Med. 361 2009 1676 1687
21. J.T. Crawley, and M.A. Scully Thrombotic thrombocytopenic purpura: Basic pathophysiology and therapeutic strategies Hematology Am Soc Hematol Educ Program. 2013 2013 292 299
22. D. Kavanagh, and T.H. Goodship Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations Hematology Am Soc Hematol Educ Program. 2011 2011 15 20
23. E.L. Amorosi, and J.E. Ultmann Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature Medicine 45 1966 139 159
24. A. Alvarez-Larrán, J. del Río-Garma, M. Pujol, J. de la Rubia, M. Hernández-Jodra, and M. Borrell Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: A comparison of presenting clinical characteristics and response to treatment Ann Hematol. 88 2009 973 978
25. B.M. Hawkins, M. Abu-Fadel, S.K. Vesely, and J.N. George Clinical cardiac involvement in thrombotic thrombocytopenic purpura: A systematic review Transfusion 48 2008 382 392
26. K. Gandhi, W.S. Aronow, H. Desai, H. Amin, M. Sharma, and H.M. Lai Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: A single-center experience Clin Cardiol. 33 2010 213 216
27. S.R. Cataland, M.A. Scully, J. Paskavitz, P. Maruff, L. Witkoff, and M. Jin Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura Am J Hematol. 86 2011 87 89
28. V. McDonald, R. Liesner, J. Grainger, M. Gattens, S.J. Machin, and M. Scully Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: Clinical management and the use of ADAMTS 13 assays Blood Coagul Fibrinolysis 21 2010 245 250
29. J.A. Reese, D.S. Muthurajah, J.A. Kremer Hovinga, S.K. Vesely, D.R. Terrell, and J.N. George Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features Pediatr Blood Cancer 60 2013 1676 1682
30. L.A. Lotta, H.M. Wu, I.J. Mackie, M. Noris, A. Veyradier, and M.A. Scully Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura Blood. 120 2012 440 448
31. W.A. Hassenpflug, U. Budde, S. Schneppenheim, and R. Schneppenheim Inherited thrombotic thrombocytopenic purpura in children Semin Thromb Hemost. 40 2014 487 492
32. M. Morioka, M. Matsumoto, M. Saito, K. Kokame, T. Miyata, and Y. Fujimura A first bout of thrombotic thrombocytopenic purpura triggered by herpes simplex infection in a 45-year-old nulliparous female with Upshaw-Schulman syndrome Blood Transfus. 12 Suppl 1 2014 s153 s155
33. C. Mele, G. Remuzzi, and M. Noris Hemolytic uremic syndrome Semin Immunopathol. 36 2014 399 420
34. A.X. Garg, R.S. Suri, N. Barrowman, F. Rehman, D. Matsell, and M.P. Rosas-Arellano Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: A systematic review, meta-analysis, and meta-regression JAMA 290 2003 1360 1370
35. M. Salvadori, and E. Bertoni Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations World J Nephrol. 2 2013 56 76
36. V. Fremeaux-Bacchi, F. Fakhouri, A. Garnier, F. Bienaime, M.A. Dragon-Durey, and S. Ngo Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults Clin J Am Soc Nephrol. 8 2013 554 562
37. H.M. Tsai Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome Am J Med. 126 2013 200 209
38. M. Le Quintrec, J. Zuber, B. Moulin, N. Kamar, M. Jablonski, and A. Lionet Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome Am J Transplant. 13 2013 663 675
39. J.N. George, and R.S. Charania Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia Semin Thromb Hemost. 39 2013 153 160
40. M. Scully, and T. Goodship How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome Br J Haematol. 164 2014 759 766
41. Y. Delmas, B. Vendrely, B. Clouzeau, H. Bachir, H.N. Bui, and A. Lacraz Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: Outcome with eculizumab Nephrol Dial Transplant. 29 2014 565 572
42. N. Noël, G. Maigné, G. Tertian, N. Anguel, X. Monnet, and J.M. Michot Hemolysis and schistocytosis in the emergency department: Consider pseudothrombotic microangiopathy related to vitamin B12 deficiency QJM. 106 2013 1017 1022
43. E. Cornec-Le Gall, Y. Delmas, L. De Parscau, L. Doucet, H. Ogier, and J.F. Benoist Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency Am J Kidney Dis. 63 2014 119 123
44. G. Rock, J.G. Kelton, K.H. Shumak, N.A. Buskard, D.M. Sutton, and W.B. Benny Laboratory abnormalities in thrombotic thrombocytopenic purpura. Canadian Apheresis Group Br J Haematol. 103 1998 1031 1036
45. J.N. George How I treat patients with thrombotic thrombocytopenic purpura: 2010 Blood. 116 2010 4060 4069
46. E.R. Burns, Y. Lou, and A. Pathak Morphologic diagnosis of thrombotic thrombocytopenic purpura Am J Hematol. 75 2004 18 21
47. G. Zini, G. d'Onofrio, C. Briggs, W. Erber, J.M. Jou, S.H. Lee International Council for Standardization in Haematology (ICSH) ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes Int J Lab Hematol. 34 2012 107 116
48. J.N. George, and Z.L. Al-Nouri Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes Hematology Am Soc Hematol Educ Program. 2012 2012 604 609
49. S.R. Cataland, V.M. Holers, S. Geyer, S. Yang, and H.M. Wu Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiates aHUS from TTP Blood. 123 2014 3733 3738
50. S.A. Just, N. Marcussen, U. Sprogoe, P. Koefoed-Nielsen, and C. Bistrup Acute antibody-mediated rejection after ABO-incompatible kidney transplantation treated successfully with antigen-specific immunoadsorption Nephrol Dial Transplant. 25 2010 310 313
51. H.M. Tsai, and E.C. Lian Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura N Engl J Med 339 1998 1585 1594
52. H.E. Gerritsen, P.L. Turecek, H.P. Schwarz, B. Lammle, and M. Furlan Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP) Thromb Haemost. 82 1999 1386 1389
53. M. Bohm, T. Vigh, and I. Scharrer Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13) Ann Hematol. 81 2002 430 435
54. J.L. Whitelock, L. Nolasco, A. Bernardo, J. Moake, J.F. Dong, and M.A. Cruz ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate J Thromb Haemost. 2 2004 485 491
55. W. Zhou, and H.M. Tsai An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations Thromb Haemost 91 2004 806 811
56. S. Kato, M. Matsumoto, T. Matsuyama, A. Isonishi, H. Hiura, and Y. Fujimura Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity Transfusion 46 2006 1444 1452
57. K. Kokame, Y. Nobe, Y. Kokubo, A. Okayama, and T. Miyata FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay Br J Haematol. 129 2005 93 100
58. F. Peyvandi, S. Ferrari, S. Lavoretano, M.T. Canciani, and P.M. Mannucci Von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura Br J Haematol. 127 2004 433 439
59. F. Peyvandi, S. Lavoretano, R. Palla, H.B. Feys, K. Vanhoorelbeke, and T. Battaglioli ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission Haematologica 93 2008 232 239
60. M. Furlan, R. Robles, M. Galbusera, G. Remuzzi, P.A. Kyrle, and B. Brenner Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome N Engl J Med 339 1998 1578 1584
61. M. Rieger, P.M. Mannucci, J.A. Kremer Hovinga, A. Herzog, G. Gerstenbauer, and C. Konetschny ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases Blood. 106 2005 1262 1267
62. P.I. Tarr, C.A. Gordon, and W.L. Chandler Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome Lancet 365 2005 1073 1086
63. D.R. Pollard, W.M. Johnson, H. Lior, S.D. Tyler, and K.R. Rozee Rapid and specific detection of verotoxin genes in Escherichia coli by the polymerase chain reaction J Clin Microbiol. 28 1990 540 545
64. H. Schmidt, L. Beutin, and H. Karch Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157:H7 strain EDL 933 Infect Immun. 63 1995 1055 1061
65. E. Bresin, E. Rurali, J. Caprioli, P. Sanchez-Corral, V. Fremeaux-Bacchi, S. Rodriguez de Cordoba European Working Party on Complement Genetics in Renal Diseases Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype J Am Soc Nephrol. 24 2013 475 486
66. G.A. Rock, K.H. Shumak, N.A. Buskard, V.S. Blanchette, J.G. Kelton, and R.C. Nair Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group N Engl J Med 325 1991 393 397
67. J. Schwartz, J.L. Winters, A. Padmanabhan, R.A. Balogun, M. Delaney, and M.L. Linenberger Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The sixth special issue J Clin Apher. 28 2013 145 284
68. M. Scully, B.J. Hunt, S. Benjamin, R. Liesner, P. Rose, and F. Peyvandi Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies Br J Haematol. 158 2012 323 335
69. C.S. Kessler, B.A. Khan, and K. Lai-Miller Thrombotic thrombocytopenic purpura: A hematological emergency J Emerg Med. 43 2012 538 544
70. L. Nguyen, X. Li, D. Duvall, D.R. Terrell, S.K. Vesely, and J.N. George Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: The experience of the Oklahoma Registry, 1989 through 2006 Transfusion 48 2008 349 357
71. E.A. Scott, K.E. Puca, B.C. Pietz, B.K. Duchateau, and K.D. Friedman Comparison and stability of ADAMTS13 activity in therapeutic plasma products Transfusion 47 2007 120 125
72. G. Rock, K.H. Shumak, D.M. Sutton, N.A. Buskard, R.C. Nair, and G. Adams Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura Br J Haematol. 94 1996 383 386
73. T.J. Raife, K.D. Friedman, and D.M. Dwyre The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: Reconsideration of treatment with cryopoor plasma Transfusion 46 2006 74 79
74. J. Del Río-Garma, A. Alvarez-Larrán, C. Martínez, J. Muncunill, D. Castellà, and R.J. de la Rubia Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: A multicentric, prospective cohort study Br J Haematol. 143 2008 39 45
75. M. Lozano, J. Cid, and T.H. Muller Plasma treated with methylene blue and light: Clinical efficacy and safety profile Transfus Med Rev. 27 2013 235 240
76. K.L. O'Brien, T.H. Price, C. Howell, and M. Delaney The use of 50% albumin/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura J Clin Apher. 28 2013 416 421
77. M. Lozano, J. Narváez, A. Faúndez, R. Mazzara, J. Cid, and J.M. Jou Recuento de plaquetas y volumen plaquetario medio en la población española Med Clin (Barc) 110 1998 774 777
78. N. Bandarenko, and M.E. Brecher United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange J Clin Apher. 13 1998 133 141
79. W.R. Bell, H.G. Braine, P.M. Ness, and T.S. Kickler Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients N Engl J Med. 325 1991 398 403
80. C.L. Balduini, L. Gugliotta, M. Luppi, L. Laurenti, C. Klersy, and C. Pieresca High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: A randomized study Ann Hematol. 89 2010 591 596
81. B. Garvey Rituximab in the treatment of autoimmune haematological disorders Br J Haematol. 141 2008 149 169
82. A. Froissart, M. Buffet, A. Veyradier, P. Poullin, F. Provot, and S. Malot Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center Crit Care Med. 40 2012 104 111
83. J. de la Rubia, F. Moscardó, M.J. Gómez, R. Guardia, P. Rodríguez, A. Sebrango Grupo Español de Aféresis Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study Transfus Apher Sci. 43 2010 299 303
84. M. Scully, V. McDonald, J. Cavenagh, B.J. Hunt, I. Longair, and H. Cohen A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura Blood. 118 2011 1746 1753
85. E. Bresin, S. Gastoldi, E. Daina, D. Belotti, E. Pogliani, and P. Perseghin Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies Thromb Haemost. 101 2009 233 238
86. G. Rock, W.F. Clark, D. Anderson, B. Benny, D. Sutton, and P. Leblond ADAMTS-13 may not predict disease or outcome in patients with thrombotic thrombocytopenic purpura Thromb Res. 131 2013 308 312
87. J.P. Westwood, H. Webster, S. McGuckin, V. McDonald, S.J. Machin, and M. Scully Rituximab for thrombotic thrombocytopenic purpura: Benefit of early administration during acute episodes and use of prophylaxis to prevent relapse J Thromb Haemost. 11 2013 481 490
88. V. McDonald, K. Manns, I.J. Mackie, S.J. Machin, and M.A. Scully Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura J Thromb Haemost. 8 2010 1201 1208
89. D. Provan, T. Butler, M.L. Evangelista, S. Amadori, A.C. Newland, and R. Stasi Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults Haematologica 92 2007 1695 1698
90. F. Zaja, M.L. Battista, M.T. Pirrotta, S. Palmieri, M. Montagna, and N. Vianelli Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura Haematologica 93 2008 930 933
91. F. Beloncle, M. Buffet, J.P. Coindre, N. Munoz-Bongrand, S. Malot, and F. Pène Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: The French TMA Reference Center experience Transfusion 52 2012 2436 2444
92. S.R. Cataland, M. Jin, X.L. Zheng, J.N. George, and H.M. Wu An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura J Thromb Haemost. 4 2006 1162 1164
93. S.R. Cataland, M. Jin, S. Lin, E.H. Kraut, J.N. George, and H.M. Wu Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura Am J Hematol. 83 2008 911 915
94. B. Plaimauer, J.A. Kremer Hovinga, C. Juno, M.J. Wolfsegger, S. Skalicky, and M. Schmidt Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies J Thromb Haemost. 9 2011 936 944
95. A. Schiviz, M. Resch, E. Farnleitner, H. Rottensteiner, F. Scheiflinger, and H.P. Schwarz Preclinical efficacy testing of Baxter's recombinant ADAMTS13 in a mouse model of TTP Blood (ASH Annual Meeting Atlanta) 120 2012 2216
96. M.D. Vergouwen, V.L. Knaup, J.J. Roelofs, O.J. de Boer, and J.C. Meijers Effect of recombinant ADAMTS-13 on microthrombosis and brain injury after experimental subarachnoid hemorrhage J Thromb Haemost. 12 2014 943 947
97. M.C. Berndt, and R.K. Andrews Thrombotic thrombocytopenic purpura: Reducing the risk J Clin Invest 121 2011 522 524
98. G.W. Li, S. Rambally, J. Kamboj, S. Reilly, J.L. Moake, and M.M. Udden Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: A case report Transfusion 54 2014 1221 1224
99. F. Callewaert, J. Roodt, H. Ulrichts, T. Stohr, W.J. van Rensburg, and S. Lamprecht Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura Blood. 120 2012 3603 3610
100. K.K. Swisher, D.R. Terrell, S.K. Vesely, J.A. Kremer Hovinga, B. Lammle, and J.N. George Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura Transfusion 49 2009 873 887
101. J.L. Winters, A.A. Pineda, B.C. McLeod, and K.M. Grima Therapeutic apheresis in renal and metabolic diseases J Clin Apher 15 2000 53 73
102. Z.M. Szczepiorkowski, N. Bandarenko, H.C. Kim, M.L. Linenberger, M.B. Marques, and R. Sarode Guidelines on the use of therapeutic apheresis in clinical practice: Evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis J Clin Apher. 22 2007 106 175
103. Z.M. Szczepiorkowski, J.L. Winters, N. Bandarenko, H.C. Kim, M.L. Linenberger, and M.B. Marques Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis J Clin Apher. 25 2010 83 177
104. T. Kwon, M.A. Dragon-Durey, M.A. Macher, V. Baudouin, A. Maisin, and M. Peuchmaur Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome Nephrol Dial Transplant. 23 2008 2088 2090
105. M. Noris, J. Caprioli, E. Bresin, C. Mossali, G. Pianetti, and S. Gamba Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype Clin J Am Soc Nephrol 5 2010 1844 1859
106. R.P. Rother, S.A. Rollins, C.F. Mojcik, R.A. Brodsky, and L. Bell Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria Nat Biotechnol. 25 2007 1256 1264
107. J. Nurnberger, T. Philipp, O. Witzke, S.A. Opazo, U. Vester, and H.A. Baba Eculizumab for atypical hemolytic-uremic syndrome N Engl J Med 360 2009 542 544
108. C. Fernández de Larrea, F. Cofan, F. Oppenheimer, J.M. Campistol, G. Escolar, and M. Lozano Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation Transplantation 89 2010 903 904
109. C.M. Legendre, C. Licht, and C. Loirat Eculizumab in atypical hemolytic-uremic syndrome N Engl J Med 369 2013 1379 1380
110. G.M. Keating Eculizumab: A review of its use in atypical haemolytic uraemic syndrome Drugs 73 2013 2053 2066
111. F. Fakhouri, V. Fremeaux-Bacchi, and C. Loirat Atypical hemolytic uremic syndrome: From the rediscovery of complement to targeted therapy Eur J Intern Med 24 2013 492 495
112. J.I. Nishimura, M. Yamamoto, S. Hayashi, K. Ohyashiki, K. Ando, and A.L. Brodsky Genetic variants in C5 and poor response to eculizumab N Engl J Med 370 2014 632 639
113. E.K. Wong, T.H. Goodship, and D. Kavanagh Complement therapy in atypical haemolytic uraemic syndrome (aHUS) Mol Immunol. 56 2013 199 212
114. J. Menne, M. Nitschke, R. Stingele, M. Abu-Tair, J. Beneke, and J. Bramstedt Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: Case-control study BMJ 345 2012 e4565
115. J.T. Kielstein, G. Beutel, S. Fleig, J. Steinhoff, T.N. Meyer, and C. Hafer Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: An analysis of the German STEC-HUS registry Nephrol Dial Transplant. 27 2012 3807 3815
116. B.L. Laskin, J. Goebel, S.M. Davies, and S. Jodele Small vessels, big trouble in the kidneys and beyond: Hematopoietic stem cell transplantation-associated thrombotic microangiopathy Blood. 118 2011 1452 1462
117. E.D. Batts, and H.M. Lazarus Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: Real progress or are we still waiting? Bone Marrow Transplant. 40 2007 709 719
118. J.N. George Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: Defining a disorder Bone Marrow Transplant. 41 2008 917 918
119. B.S. Cho, C.K. Min, K.S. Eom, Y.J. Kim, H.J. Kim, and S. Lee Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Bone Marrow Transplant. 41 2008 813 820
120. S. Jodele, C. Licht, J. Goebel, B.P. Dixon, K. Zhang, and T.A. Sivakumaran Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy Blood. 122 2013 2003 2007
121. S. Jodele, T. Fukuda, A. Vinks, K. Mizuno, B.L. Laskin, and J. Goebel Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy Biol Blood Marrow Transplant. 20 2014 518 525
122. R. Peffault de Latour, A. Xhaard, V. Fremeaux-Bacchi, P. Coppo, A.M. Fischer, and D. Helley Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy Br J Haematol. 161 2013 279 280
123. D. Hart, R. Sayer, R. Miller, S. Edwards, A. Kelly, and T. Baglin Human immunodeficiency virus associated thrombotic thrombocytopenic purpura - Favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy Br J Haematol. 153 2011 515 519
124. A.K. Tadakamalla, S.K. Talluri, and S. Besur Pseudo-thrombotic thrombocytopenic purpura: A rare presentation of pernicious anemia N Am J Med Sci. 3 2011 472 474